University of Chicago

Questions discussed in this category

For relapsed/refractory myeloma, how long of a disease-free interval from first autologous transplant do you recommend before considering a second autologous transplant?

1 Answer available

How would one alter therapy in a transplant-ineligible AL amyloidosis with less than a complete response to six cycles of Dara-CyBorD?

Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?

2 Answers available

How do you approach a patient with an anaplastic plasmacytoma without systemic evidence of disease in the bone marrow?

What about multiple anaplastic plasmacytoma without bone marrow involvement?

2 Answers available

Do you continue bortezomib past 8 cycles for transplant ineligible patients with multiple myeloma on VRd who are tolerating therapy well with no neuropathy?

Would you use MRD status to guide your decision making?

1 Answer available

Papers discussed in this category

The Lancet. Oncology, 2019-01

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

J Clin Oncol, 2020 Oct 06

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.

Journal of clinical pathology, 2017-09

Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.

Leukemia, 2018-06

Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset.

Blood Cancer J, 2021 Jan 11

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

N Engl J Med,

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Lancet Haematol,

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Leukemia, 2020 Jul 21

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.

Related Topics